Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr Reddy’s Faces US Class Action Case Heat

Executive Summary

Pressure builds on Dr Reddy’s Laboratories after at least two US law firms press ahead with a class action case against the company. Analysts appear unperturbed, however – at least for now – about the possibility of any material implications.

You may also be interested in...

Another Dr Reddy’s Plant Runs Afoul Of German Regulator

Dr Reddy’s Laboratories has suffered another blow, with a second manufacturing facility failing to pass muster with the German regulator. While the plant doesn’t currently make supplies to the EU, the firm’s recent run of compliance deviations threatens to erode investor confidence.

FDA Slams Hetero For Oversized Tablets And Dirty Equipment

In a recent FDA warning letter to Hetero Labs in Hyderabad, India, investigators chastise the firm for lax GMP practices. Hetero joins a growing number of manufacturers in the city that have been targeted by FDA and EU regulators for GMP violations this year.

Pre-work Rigour, 'Clean' Documentation Key As FDA Unlocks Remote Inspection Tools

A senior Parexel executive and ex-FDA pharmaceutical quality assessor emphasizes at a conclave why “first impressions matter now more than ever” as the agency  deploys complex alternate inspections tools which the pandemic provided, and that companies need to ensure that they get things right the first time.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts